Data / Drug companies / Sola Pharmaceuticals, LLC
Sola Pharmaceuticals, LLC: 36 products in the FDA NDC directory, labeler code 70512
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sola Pharmaceuticals, LLC (labeler code 70512) lists 36 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 26 prescription drugs, 10 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 3, 2025.
The request: Watch Sola Pharmaceuticals, LLC (FDA labeler code 70512): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70512
- Products in commercial distribution
- 36
- Packages
- 46
- Finished drugs by generic name
- 25
- Prescription products
- 26
- Over the counter products
- 10
- Flagged as original packager
- 35 of 35 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- May 25, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 26 | 72.2% |
| Over the counter monograph drugs | 8 | 22.2% |
| New drug applications (NDA) | 2 | 5.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 72.2% |
| Over the counter drugs | 10 | 27.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Ketorolac tromethamine | 4 | 69 |
| Diclofenac sodium | 2 | 109 |
| Dimethyl fumarate | 2 | 20 |
| Diclofenac potassium | 2 | 42 |
| Lidocaine 4% | 2 | 45 |
| Phenylephrine hydrochloride | 2 | 77 |
| Ibuprofen | 2 | 190 |
| Oxaprozin | 2 | 8 |
| Ropivacaine hydrochloride | 2 | 20 |
| Neuracin topical analgesic gel | 1 | 1 |
| Diclofenac sodium 1% | 1 | 3 |
| Ofloxacin ophthalmic solution usp, 0.3% | 1 | 2 |
| Olopatadine hcl | 1 | 2 |
| Cyanocobalamin | 1 | 25 |
| Carboprost tromethamine | 1 | 22 |
| Sodium chloride | 1 | 71 |
| Lidocaine / menthol / methyl salicylate | 1 | 1 |
| Baclofen | 1 | 65 |
| Cabergoline | 1 | 9 |
| Lidocaine/menthol | 1 | 1 |
| Cyclobenzaprine hydrochloride | 1 | 61 |
| Synoflex patch | 1 | 1 |
| Capsaicin 0.025% topical patch | 1 | 1 |
| Lidocaine | 1 | 216 |
| Diclofenac sodium topical | 1 | 11 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch | 7 | 19.4% |
| Solution/ drops | 4 | 11.1% |
| Injection | 4 | 11.1% |
| Injection, solution | 4 | 11.1% |
| Tablet | 4 | 11.1% |
| Solution | 3 | 8.3% |
| Tablet, film coated | 3 | 8.3% |
| Gel | 2 | 5.6% |
| Capsule, delayed release | 2 | 5.6% |
| Capsule | 2 | 5.6% |
| Tablet, delayed release | 1 | 2.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Oxaprozin | 70512-787 | Capsule | New drug applications (NDA) | December 3, 2025 |
| Diclofenac Sodium | 70512-784 | Tablet, delayed release | Generic drugs (ANDA) | November 14, 2025 |
| Coxanto | 70512-814 | Capsule | New drug applications (NDA) | November 3, 2025 |
| Cyclobenzaprine Hydrochloride | 70512-872 | Tablet, film coated | Generic drugs (ANDA) | July 31, 2025 |
| Baclofen | 70512-782 | Tablet | Generic drugs (ANDA) | March 21, 2025 |
| Ibuprofen | 70512-794 | Tablet | Generic drugs (ANDA) | February 14, 2025 |
| Ropivacaine hydrochloride | 70512-798 | Injection, solution | Generic drugs (ANDA) | December 1, 2024 |
| Ropivacaine hydrochloride | 70512-797 | Injection, solution | Generic drugs (ANDA) | December 1, 2024 |
| Ibuprofen | 70512-780 | Tablet | Generic drugs (ANDA) | December 1, 2024 |
| Diclofenac Potassium | 70512-900 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Ketorolac Tromethamine | 70512-844 | Injection | Generic drugs (ANDA) | October 22, 2024 |
| Diclofenac Potassium | 70512-750 | Tablet, film coated | Generic drugs (ANDA) | October 21, 2024 |
| Phenylephrine Hydrochloride | 70512-866 | Solution/ drops | Generic drugs (ANDA) | June 1, 2024 |
| Phenylephrine Hydrochloride | 70512-865 | Solution/ drops | Generic drugs (ANDA) | June 1, 2024 |
| Ofloxacin | 70512-793 | Solution/ drops | Generic drugs (ANDA) | April 30, 2024 |
| Ketorolac Tromethamine | 70512-790 | Solution | Generic drugs (ANDA) | April 15, 2024 |
| Lidocaine 4% Patch | 70512-812 | Patch | Over the counter monograph drugs | October 12, 2023 |
| Carboprost tromethamine | 70512-859 | Injection, solution | Generic drugs (ANDA) | September 25, 2023 |
| Ketorolac Tromethamine | 70512-843 | Injection | Generic drugs (ANDA) | July 1, 2023 |
| Ketorolac Tromethamine | 70512-842 | Injection | Generic drugs (ANDA) | July 1, 2023 |
| Diclofenac Sodium | 70512-810 | Solution | Generic drugs (ANDA) | July 1, 2023 |
| Cabergoline | 70512-860 | Tablet | Generic drugs (ANDA) | May 8, 2023 |
| Dimethyl Fumarate | 70512-853 | Capsule, delayed release | Generic drugs (ANDA) | January 31, 2023 |
| Dimethyl Fumarate | 70512-852 | Capsule, delayed release | Generic drugs (ANDA) | January 31, 2023 |
| Triceptin | 70512-017 | Patch | Over the counter monograph drugs | December 5, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.